Vanguard Capital Management
KROS icon

Vanguard Capital Management’s Keros Therapeutics KROS Stock Holding History

Vanguard Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.92M Buy
833,596
+2,175
+0.3% +$24.2K ﹤0.01% 2886
2026
Q1 		$9.18M Buy
+831,421
New +$12.8M ﹤0.01% 2777

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Vanguard Capital Management's KROS Position: Q2 2026 in Review

Vanguard Capital Management increased its Keros Therapeutics (KROS) stake by 0.26% in Q2 2026, buying an estimated $24.2K and bringing the position to 833,596 shares worth $8.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2886.

Vanguard Capital Management first reported a position in KROS in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.18M in Q1 2026. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Vanguard Capital Management held 833,596 shares of Keros Therapeutics worth $8.92M as of Q2 2026.
  • Vanguard Capital Management bought 2,175 Keros Therapeutics shares in Q2 2026, an estimated $24.2K.
  • Keros Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2886 holding.
  • Vanguard Capital Management first reported a position in Keros Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Keros Therapeutics position peaked at $9.18M in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.